

Ana Ruiz-Garcia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5010960/publications.pdf>

Version: 2024-02-01

50
papers

2,054
citations

331670

21
h-index

233421

45
g-index

52
all docs

52
docs citations

52
times ranked

2882
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. <i>Lancet Oncology</i> , 2009, 10, 794-800.	10.7	287
2	Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-HER Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 3337-3344.	1.6	247
3	PAMPA—a drug absorption in vitro model. <i>European Journal of Pharmaceutical Sciences</i> , 2004, 21, 429-441.	4.0	187
4	Phase II study of sunitinib as second-line treatment for advanced gastric cancer. <i>Investigational New Drugs</i> , 2011, 29, 1449-1458.	2.6	179
5	Establishing Best Practices and Guidance in Population Modeling: An Experience With an Internal Population Pharmacokinetic Analysis Guidance. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2013, 2, 1-8.	2.5	140
6	A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth) receptor tyrosine kinase inhibitor, in patients with advanced non-small-cell lung cancer after prior chemotherapy and erlotinib. <i>Cancer</i> , 2014, 120, 1145-1154.	4.1	125
7	Pharmacokinetics in Drug Discovery. <i>Journal of Pharmaceutical Sciences</i> , 2008, 97, 654-690.	3.3	116
8	Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2012, 30, 2352-2363.	2.6	62
9	Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A phase I dose-escalation study. <i>Lung Cancer</i> , 2010, 70, 180-187.	2.0	41
10	A phase I, open-label, mass balance study of [¹⁴ C] dacomitinib (PF-00299804) in healthy male volunteers. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 379-385.	2.3	38
11	Kinetic modelling of passive transport and active efflux of a fluoroquinolone across Caco-2 cells using a compartmental approach in NONMEM. <i>Xenobiotica</i> , 2005, 35, 1067-1088.	1.1	35
12	Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. <i>Anti-Cancer Drugs</i> , 2018, 29, 271-280.	1.4	33
13	Transintestinal secretion of ciprofloxacin, grepafloxacin and sparfloxacin: in vitro and in situ inhibition studies. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2003, 55, 241-246.	4.3	32
14	Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 1159-1173.	2.0	30
15	In situ kinetic modelling of intestinal efflux in rats: functional characterization of segmental differences and correlation within vitro results. <i>Biopharmaceutics and Drug Disposition</i> , 2007, 28, 229-239.	1.9	29
16	Intrinsic Absolute Bioavailability Prediction in Rats Based on In Situ Absorption Rate Constants and/or In Vitro Partition Coefficients: Fluoroquinolones. <i>Journal of Pharmaceutical Sciences</i> , 2000, 89, 1395-1403.	3.3	28
17	Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2019, 46, 211-222.	1.8	26
18	Kinetic Characterization of Secretory Transport of a New Ciprofloxacin Derivative (CNV97100) across Caco-2 Cell Monolayers**This work has been submitted for the partial fulfillment of the requirement for a Ph.D. Degree in Pharmaceutics at the University of Valencia, Valencia, Spain. <i>Journal of Pharmaceutical Sciences</i> , 2002, 91, 2511-2519.	3.3	23

#	ARTICLE	IF	CITATIONS
19	Kinetic modelling of the intestinal transport of sarafloxacin. Studies in situ in rat and in vitro in Caco-2 cells. <i>Journal of Drug Targeting</i> , 2005, 13, 199-212.	4.4	23
20	A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. <i>Annals of Oncology</i> , 2012, 23, 119-127.	1.2	23
21	Pharmacokinetic/Pharmacodynamic Modeling to Support the Reapproval of Gemtuzumab Ozogamicin. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1006-1017.	4.7	23
22	Sunitinib Plus Erlotinib for the Treatment of Advanced/Metastatic Non-Small-Cell Lung Cancer: A Lead-In Study. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1406-1416.	1.1	22
23	Effect of food on the bioavailability of palbociclib. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 527-533.	2.3	22
24	Role of the Equilibrative and Concentrative Nucleoside Transporters in the Intestinal Absorption of the Nucleoside Drug, Ribavirin, in Wild-Type and Ent1(Δ) Mice. <i>Molecular Pharmaceutics</i> , 2012, 9, 2442-2449.	4.6	21
25	Pharmacokinetics, bioavailability and absorption of flumequine in the rat. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 1999, 48, 253-258.	4.3	20
26	Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study. <i>British Journal of Cancer</i> , 2013, 108, 1393-1401.	6.4	20
27	A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 555-562.	2.0	19
28	Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 307-319.	2.3	18
29	Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 223-230.	2.0	18
30	Methods and strategies for assessing uncontrolled drug-drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2016, 43, 123-135.	1.8	18
31	A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2010, 103, 993-1000.	6.4	17
32	Pharmacokinetics of Murine p75-Fc Fusion Protein and MP6-XT22 Anti-Murine TNF-α mAb in Mice. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2007, 12, 52-56.	0.8	13
33	Effect of axitinib on the QT interval in healthy volunteers. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 619-628.	2.3	13
34	Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid Tumors. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 605-616.	2.0	13
35	A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 709-722.	2.3	12
36	Pharmacokinetics of single-agent axitinib across multiple solid tumor types. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 1279-1289.	2.3	12

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetic Models to Characterize the Absorption Phase and the Influence of a Proton Pump Inhibitor on the Overall Exposure of Dacomitinib. <i>Pharmaceutics</i> , 2020, 12, 330.	4.5	12
38	Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 703-712.	2.3	11
39	Kinetic Modeling of Triamterene Intestinal Absorption and its Inhibition by Folic Acid and Methotrexate. <i>Journal of Drug Targeting</i> , 2003, 11, 215-223.	4.4	9
40	An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 451-459.	2.3	6
41	Mathematical modeling of oral absorption and bioavailability of a fluoroquinolone after its precipitation in the gastrointestinal tract. <i>Xenobiotica</i> , 2013, 43, 745-754.	1.1	5
42	Population Pharmacokinetic/Pharmacodynamic Evaluation of the Relationship between Glasdegib Treatment/ Exposure and Overall Survival in AML Patients. <i>Blood</i> , 2018, 132, 1450-1450.	1.4	5
43	Phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).. <i>Journal of Clinical Oncology</i> , 2011, 29, 5561-5561.	1.6	5
44	Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study. <i>Investigational New Drugs</i> , 2013, 31, 1487-1498.	2.6	4
45	Pharmacometric dose optimization of buprenorphine in neonatal opioid withdrawal syndrome. <i>Clinical and Translational Science</i> , 2021, 14, 2171-2183.	3.1	4
46	Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. <i>Clinical and Translational Science</i> , 2021, 14, 184-193.	3.1	3
47	Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic Malignancies. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 349-359.	2.0	2
48	Pharmacokinetics and Pharmacodynamics of Tyrosine Kinase Inhibitors. , 2016, , 121-150.		1
49	Abstract 3887: Population pharmacokinetic/pharmacodynamic evaluation of the relationship between glasdegib exposure and safety endpoints in cancer patients. , 2019, , .		1
50	Abstract 3889: Population pharmacokinetic/pharmacodynamic evaluation of the effect of glasdegib exposure on cardiac repolarization (QT interval) in cancer patients. , 2019, , .		1